Biopharma News

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

The Indiana Biosciences Research Institute will accelerate collaboration and focus on human-health solutions.

Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.

Merck KGaA plans to build a new biomanufacturing facility in Nantong, China.

Shire's agreement to acquire ViroPharma will strengthen its rare-disease portfolio.

ISPE names Novartis' US Flu Cell Culture facility as award winner.

KaloBios Pharmaceuticals receives FDA Orphan Drug Designation for KB001-A in treatment of cystic fibrosis patients.

GSK and the Gates Foundation will invest a combined $1.8 million in early stage research into vaccine thermostability.

Big pharma companies Novartis, Amgen, and Bristol-Myers Squibb announce positive third-quarter 2013 results.

Amarin cuts staff in half after an FDA committee rejects its product label expansion.

Abbott?s third-quarter 2013 global sales increased slightly but were affected by a disruption in the International Nutrition business.

J&J announces 2013 third-quarter sales increased 3% over 2012 third-quarter sales.

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

GlaxoSmithKline?s sale of its thrombosis brands is part of a focus on its late-stage pipeline.

Merck announced plans to reduce its workforce by 8,500 and move its headquarters in order to sharpen its commercial and R&D focus.

Merck & Co. has received a Complete Response Letter from FDA for the resubmission of its new drug application for sugammadex sodium injection.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

Cell Medica, a T cell therapeutics company, has opened a European manufacturing facility in Berlin-Buch, Germany to develop, manufacture, and market treatments of infections and cancers related to oncogenic viruses.

AstraZeneca, Bristol-Myers Squibb recall certain lots of of their antidiabetes drug Bydureon (eventide) due to manufacturing records that batches may contain underfilled vials.

Unilife grants Sanofi long-term exclusivity for the use of Unilife?s prefilled syringe with Sanofi?s Lovenox.

Myriad Genetics and AstraZeneca expand their companion diagnostic pact for AztraZeneca?s investigational drug candidate olaparib.

Following passage in the California Assembly, the California State Senate passes legislation to specify requirements for dispensing biosimilars.

Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.

Amarin released the submission of an sNDA to FDA seeking approval for Novasep Group.

Sanofi Pasteur has purchased Freeslate?s Biologics Formulation System for accelerating research in vaccine and protein formulation development.

Santaris Pharma and Shire have extended their partnership in the rare genetic disease space.

Vical's restructuring will leave the company with approximately 74 employees.